NEUROLOGICAL DISORDERS

摘要

The use of a compound of Formula (VIII) in the manufacture of a medicament for the treatment of or the prevention of neurological disorders, in a warm-blooded mammal, wherein A and B are selected from: Formula (IX) or Formula (X) such that when A is of Formula (X) then B is of Formula (IX) and when A is of Formula (IX) then B is of Formula (X). R1 is selected from hydrogen, halo, aryl, carbamoyl, N-C1-4alkylcarbamoyl or NN-di-C1-4alkylcarbamoyl; D is selected from C1-4alkylene, C1-4alkenylene or alkynylene; R2 is selected from hydrogen, C1-4alkyl or hydroxy; R3 is selected from hydrogen, hydroxy, halo, PO4, C1-4alkoxy, or a group of the formula: -E-F-G-H wherein: E is selected from: (a), (b), (c), (d), (e), or (f); F is selected from: (a), (b), or a direct bond; G is selected from C1-6alkyl, or a direct bond; H is selected from hydrogen, C1-4alkoxy, or optionally substituted aryl; heteroaryl, or carbocyclyl; R4 and R5 are independently selected from methyl, ethyl or phenyl, or together with the nitrogen atom to which they are attached form a ring selected from pyrrolidine, piperidine or morpholine; R6 is selected from hydrogen, C1-4alkyl; C1-4alkoxy, halo, or a ring fused phenyl group fused via carbons 3 and 4 on the phenyl group of Formula (X); R7 and R8 are either both hydrogen or when A is of Formula (X) may be joined either via a sulphur atom, via -CH2- or via -C2H4; R9 is selected from hydrogen or C1-4alkyl; and n is 2 or 3; or a pharmaceutically acceptable salt, prodrug or solvate thereof. Processes for their preparation of compounds of Formula (VIII) are described, as are compositions containing them and their use.